Compare

Ionis Pharmaceuticals/$IONS

1D1W1M3M6MYTD1Y5YMAX

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Ticker
$IONS
Sector
Health
Primary listing
NASDAQ
Employees
1,485

IONS Metrics

BasicAdvanced
$4.6B
-
-$3.32
0.40
-

What the Analysts think about IONS

Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Analyst projections of the future price of Ionis Pharmaceuticals stock.

Bulls say / Bears say

DAWNZERA is showing a stronger launch trajectory: third-quarter US sales reached $37 million, up from $0.7 million a year earlier, and Ionis reaffirmed its $110–120 million 2026 sales guidance. The product is becoming a meaningful source of commercial growth. (Ionis Pharmaceuticals)
ZANVASTRO gives Ionis a new wholly owned growth opportunity in a rare neurological disease, with FDA approval as the first disease-modifying treatment for Alexander disease and commercial patients already starting treatment. Its quarterly dosing and overseas partner may help broaden its reach. (Ionis Pharmaceuticals, SEC)
Two late-stage programmes have delivered positive Phase 3 results: sefaxersen met its primary endpoint in IgA nephropathy, while ulefnersen improved functional impairment and survival in FUS-ALS. These results add potential future approval and partnership revenue opportunities, although regulatory outcomes remain uncertain. (Ionis Pharmaceuticals, Ionis Pharmaceuticals)
TRYNGOLZA’s commercial ramp is materially slower than planned: Ionis cut its 2026 sales outlook to about $50 million from $100–110 million after third-quarter US sales of just $9 million. The reset raises doubts about how quickly the drug can establish demand in the broader severe hypertriglyceridaemia market. (Ionis Pharmaceuticals, Reuters)
Pelacarsen failed to reduce major cardiovascular events in its Phase 3 outcomes trial, despite lowering Lp(a), and the reported results have weakened the case for a major cardiovascular growth driver. This removes a substantial potential source of future commercial value from Ionis’s partnered pipeline. (Morningstar, SEC)
Ionis remains loss-making while funding several launches: third-quarter operating expenses were $373 million against $243 million in revenue, and its full-year non-GAAP operating-loss guidance is $425–475 million. Continued spending ahead of commercial growth leaves the company reliant on its cash reserves and partnered revenue to fund development. (Ionis Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.

IONS Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

IONS Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.